Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 6,72 M
EBIT 2017 -0,87 M
Net income 2017 -1,06 M
Debt 2017 -
Yield 2017 -
Sales 2018 8,03 M
EBIT 2018 -2,32 M
Net income 2018 -2,59 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 7,69x
Capi. / Sales2018 6,43x
Capitalization 51,6 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar

- No events available -

More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
08/10 INTELGENX TECHNOLOGIES : reports 2Q loss
08/10 INTELGENX TECHNOLOGIES : Reports Second Quarter 2017 Financial Results
08/10 INTELGENX TECHNOLOGIES CORP. : Investor Network: Intelgenx Technologies Corp. to..
08/09 INTELGENX TECHNOLOGIES CORP. (OTCMKT : IGXT) Files An 8-K Entry into a Material ..
08/09 INTELGENX TECHNOLOGIES CORP. : Entry into a Material Definitive Agreement (form ..
08/08 INTELGENX TECHNOLOGIES : Closes Second Tranche of Convertible Debenture Offering
08/07 INTELGENX TECHNOLOGIES : to Report Second Quarter 2017 Financial Results on Augu..
08/03 INTELGENX TECHNOLOGIES : to Report Second Quarter 2017 Financial Results on Augu..
08/03 INTELGENX TECHNOLOGIES : to Report Second Quarter 2017 Financial Results on Augu..
07/12 INTELGENX TECHNOLOGIES : Presents at BIT's 7th Annual International Symposium of..
More news
Sector news : Generic Pharmaceuticals
08/22 JOHNSON & JOHNSON : Massive California verdict expands J&J's talc battlefield
08/22 JOHNSON & JOHNSON : Massive California verdict expands J&J's talc battlefield
08/22DJBAYER : Monsanto's $57 Billion Megadeal Faces Closer EU Scrutiny -- 2nd Update
08/22 EU starts in-depth probe of Bayer, Monsanto deal
08/22DJJOHNSON & JOHNSON : J&J Wades Into Death Penalty Debate for the First Time -- Up..
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 94%
EPS Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director